October 5, 2021
AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC
Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.
By Bill Snyder